drugset

drugset / Trial / NCT04486963

A Phase Ⅱ Clinical Study of Sanhuangjingshimingwan in Wet( Neovascular)Age-related Macular Degeneration(wAMD) Subjects

NCT04486963 ↗

Phase 2 Completed 78 enrolled Tasly Pharmaceutical Group Co., Ltd

RandomizedParallel-groupQuadruple-blindTreatment

Summary

The study is to evaluate the efficacy and safety of Sanhuangjingshimingwan in Wet AMD.

Timeline

Start: 2020-07-24
Primary completion: 2022-11-01
Completion: 2022-11-15

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Sanhuangjingshimingwan	Unknown	12 g	—

Indications